7210 Wareham Drive, Tampa, FL 33647
March 15, 2026 Medifast is an MLM (multilevel marketer) that sells meal replacements and diet foods, via health coaches. Their sales declined by 36% in 2025, to $386 million. Herbalife is another MLM that sells meal replacements and appetite suppressants, via health coaches. Their weight loss product sales in North America only declined by an […]
A Tale of Two MLM Competitors Read More »
March 4, 2026 Marketdata LLC has released a new report: “The U.S. Weight Loss Market: Status Report & 2026 Forecast” This 108-page analysis tracks the current status of ALL weight loss market segments, 2025 performance, the latest dieting trends, 15 competitor profiles, with 27 tables and charts. Some findings: The total U.S. weight loss market
U.S. Weight Loss Market Now Worth $135 Billion – New Report Read More »
February 18, 2026 Based on the latest press release and annual report by Herbalife… The North America region reported net sales of $1.03 billion for the year ended December 31, 2025, down 2.0%. Worldwide weight management product sales declined 0.8% in 2025. North American sales, at $1.03 billion, accounted for 20.5% of total Herbalife sales.
Herbalife’s Weight Loss Sales Remained Stable in 2025 Read More »
Oct. 31, 2025 Zach Yadegari is the 18-year old co-founder and CEO of Cal AI, a calorie-tracking mobile app he launched from his parents’ home in Roslyn, New York, in May 2024. It has amassed 8.3 million downloads so far and growing. The company says that it nets $1.4 million per month profit, after expenses,
Sucess Story – Cal AI Weight Loss App Read More »
Sept. 3, 2025 WW announced the appointment of Alejandro Bethlen as Executive Vice President, International, effective immediately. In this role, Bethlen will oversee WeightWatchers’ business outside of the United States, driving international growth and innovation across the Company’s global footprint. “Alejandro’s international experience and commercial leadership make him uniquely suited to advance our growth outside
Weight Watchers Hires New International V.P. Read More »
August 6, 2025 Sales of Novo Nordisk’s injectable diabetes drugs including Ozempic have slowed sharply amid fierce competition and the threat of U.S. tariffs, coupled with continued competition from compounded drugs sold illegally. Novo Nordisk said sales of medications such as Ozempic – which mimic the GLP-1 gut hormone that regulates blood sugar levels and
Novo Nordisk Obesity Drugs Sales Slow – Compounders Still Selling illegally Read More »
August 5, 2025 Noom is not giving up in the fight to provide GLP-1 drugs, despite pressure from Novo and Eli Lilly to stop selling compounded meds. It is now offering a “micro dose” plan. This program provides access to GLP-1 medication (if prescribed by a clinician), but at a lower, “microdose” level compared to
Noom To Offer GLP-1 Microdose Plan Read More »
July 2, 2025 Weight Watchers announced an expanded collaboration with Novo Nordisk, which includes increased access to authentic, FDA-approved Wegovy® (semaglutide) injection through Weight Watchers Clinic. As part of the collaboration, Weight Watchers Clinic members will benefit from a simplified prescription process via NovoCare® Pharmacy. CenterWell Pharmacy®, which serves as the dispensing pharmacy for the
Weight Watchers Expands Collaboration With Novo Nordisk Read More »
April 9, 2025 (Reuters) – WW International may be preparing to file for bankruptcy in the coming months as part of a plan to hand control of the business to its creditors, the Wall Street Journal reported on Wednesday, citing people familiar with the matter. Shares of the company tumbled nearly 59% to 18 cents
Weight Watchers Prepares for Possible Bankruptcy Filing Read More »
March 24, 2025 Marketdata LLC has just published a new report: “The U.S. Weight Loss Market: Commercial (non-medical) Programs & Products”, March 2025. This is a 220-page analysis of commercial weight loss programs/companies and how they have been affected by and respond to the onslaught of the GLP-1 drugs competition. The $38 billion U.S. commercial weight loss
$38.4 Billion U.S. Commercial Weight Loss Market Pivots To Survive GLP-1 Drugs Explosion Read More »